Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome
Maartje E. Meier(Leiden University Medical Center), Natasha M. Appelman‐Dijkstra(Leiden University Medical Center), N. Bravenboer(Leiden University Medical Center), Marlous Hagelstein-Rotman(Leiden University Medical Center), Elizabeth M. Winter(Leiden University Medical Center), T.C.M. Streefland(Leiden University Medical Center)
Cited by 12
Related Papers
Poor sleep quality and later sleep timing are risk factors for osteopenia and sarcopenia in middle-aged men and women: The NEO study
|PLoS ONE|2017|113
Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study
|Journal of Bone and Mineral Research|2020|49
Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark
|The Journal of Clinical Endocrinology & Metabolism|2024|29
Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases
|Bone Reports|2021|28
Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune–Albright Syndrome
|The Journal of Clinical Endocrinology & Metabolism|2021|27